457 related articles for article (PubMed ID: 30084668)
21. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Motzer RJ; Nosov D; Eisen T; Bondarenko I; Lesovoy V; Lipatov O; Tomczak P; Lyulko O; Alyasova A; Harza M; Kogan M; Alekseev BY; Sternberg CN; Szczylik C; Cella D; Ivanescu C; Krivoshik A; Strahs A; Esteves B; Berkenblit A; Hutson TE
J Clin Oncol; 2013 Oct; 31(30):3791-9. PubMed ID: 24019545
[TBL] [Abstract][Full Text] [Related]
22. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF
Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Molina AM; Hutson TE; Nosov D; Tomczak P; Lipatov O; Sternberg CN; Motzer R; Eisen T
Eur J Cancer; 2018 May; 94():87-94. PubMed ID: 29547835
[TBL] [Abstract][Full Text] [Related]
24. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Chang E; Weinstock C; Zhang L; Fiero MH; Zhao M; Zahalka E; Ricks TK; Fourie Zirkelbach J; Qiu J; Yu J; Chen XH; Bhatnagar V; Goldberg KB; Tang S; Kluetz PG; Pazdur R; Ibrahim A; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2022 Feb; 28(3):441-445. PubMed ID: 34417198
[TBL] [Abstract][Full Text] [Related]
25. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
26. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma.
Albiges L; Barthélémy P; Gross-Goupil M; Negrier S; Needle MN; Escudier B
Ann Oncol; 2021 Jan; 32(1):97-102. PubMed ID: 33010459
[TBL] [Abstract][Full Text] [Related]
27. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
28. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
[TBL] [Abstract][Full Text] [Related]
29. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
Mayer EL; Scheulen ME; Beckman J; Richly H; Duarte A; Cotreau MM; Strahs AL; Agarwal S; Steelman L; Winer EP; Dickler MN
Breast Cancer Res Treat; 2013 Jul; 140(2):331-9. PubMed ID: 23868188
[TBL] [Abstract][Full Text] [Related]
30. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
32. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Wright KM
Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib for the treatment of kidney cancer.
Študentová H; Vitásková D; Melichar B
Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
[TBL] [Abstract][Full Text] [Related]
34. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.
Vázquez Estévez S; Anido U; Lázaro M; Fernández O; Fernández Núñez N; de Dios Álvarez N; Varela V; Campos Balea B; Agraso S; Areses MC; Iglesias L; Blanco M; Maciá S; Anton Aparicio LM
Clin Transl Oncol; 2020 Sep; 22(9):1565-1579. PubMed ID: 32062835
[TBL] [Abstract][Full Text] [Related]
35. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
Zahoor H; Rini BI
Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
[TBL] [Abstract][Full Text] [Related]
36. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Bhargava P; Robinson MO
Curr Oncol Rep; 2011 Apr; 13(2):103-11. PubMed ID: 21318618
[TBL] [Abstract][Full Text] [Related]
37. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).
Haberkorn BC; Eskens FA
Future Oncol; 2013 Jan; 9(1):13-20. PubMed ID: 23252559
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib for the treatment of renal cell carcinoma.
Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
[TBL] [Abstract][Full Text] [Related]
39. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
Stitzlein L; Rao P; Dudley R
Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
